Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.

Koutsakos, Marios; Rowntree, Louise C; Hensen, Luca; Chua, Brendon Y; van de Sandt, Carolien E; Habel, Jennifer R; Zhang, Wuji; Jia, Xiaoxiao et al. · Cell Rep Med · 2021

prospective_cohort · Level II

Where this comes from

Abstract

SARS-CoV-2 causes a spectrum of COVID-19 disease, the immunological basis of which remains ill defined. We analyzed 85 SARS-CoV-2-infected individuals at acute and/or convalescent time points, up to 102 days after symptom onset, quantifying 184 immunological parameters. Acute COVID-19 presented with high levels of IL-6, IL-18, and IL-10 and broad activation marked by the upregulation of CD38 on innate and adaptive lymphocytes and myeloid cells. Importantly, activated CXCR3<sup>+</sup>cT<sub>FH</sub>1 cells in acute COVID-19 significantly correlate with and predict antibody levels and their avidity at convalescence as well as acute neutralization activity. Strikingly, intensive care unit (ICU) patients with severe COVID-19 display higher levels of soluble IL-6, IL-6R, and IL-18, and hyperactivation of innate, adaptive, and myeloid compartments than patients with moderate disease. Our analyses provide a comprehensive map of longitudinal immunological responses in COVID-19 patients and integrate key cellular pathways of complex immune networks underpinning severe COVID-19, providing important insights into potential biomarkers and immunotherapies.

Medical subject headings